|Targets||Orexin Receptor (OX Receptor)|
|Description||TCS 1102 is a potent, dual orexin receptor antagonist with Ki values of 0.2 and 3 nM for OX2 and OX1 receptors respectively. It is a poor substrate for P-glycoprotein, which demonstrates good brain penetration when administered intraperitoneally. It were found to decrease fear and anxiety in rats 14 days after exposure to footshock. It was also found to have anxiolytic effects that were specific for HR when tested in the elevated T-maze.|
|Appearance||White to off-white Solid|
|Synonyms||N-[1,1'-Biphenyl]-2-yl-1-[2-[(1-methyl-1H-benzimidazol-2-yl)thio]acetyl-2-pyrrolidinedicarboxamide;2-PyrrolidinecarboxaMide, N-[1,1'-biphenyl]-2-yl-1-[2-[(1-Methyl-1H-benziMidazol-2-yl)thio]acetyl]-, (2S)-;(2S)-N-[1,1'-Biphenyl]-2-yl-1-[2-[(1-methyl-1H-benzimidazol-2-yl)thio]acetyl]-2-pyrrolidinecarboxamide;TCS 1102, TCS1102, TCS-1102;(2S)-1-[2-(1-methylbenzimidazol-2-yl)sulfanylacetyl]-N-(2-phenylphenyl)pyrrolidine-2-carboxamide|
|Solubility||10 mM in DMSO|
|Application||TCS 1102 was found to have anxiolytic effects.|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
|Quantity||Grams to Kilograms|
|Density||1.29±0.1 g/cm3 | Condition: Temp: 20 °C Press: 760 Torr|
IPSU is a selective, orally available and brain penetrant OX2 receptor antagonist (pKi= 7.85) with 6-fold selectivity over OX1 receptors.
Orexin B (mouse)
An orexin receptors agonist. It can stimulate feeding following central administration.
TCS-OX2-29, also known as TCSOX229, is a selective OX2 receptor antagonist (IC50 = 40 nM, pKi = 7.5) with >250-fold selectivity for hOX2R compared with hOX1R (I...
Filorexant, a selective reversible and orally bioavaliable antagonist of OX(1)R receptor and OX(2)R receptor, could probably be an effective compound in the tre...
ACT 335827 has been found to be an orexin OX1 receptor antagonist and could probably exhibit anxiolytic effects in vivo.
[Ala11,D-Leu15]-Orexin B is a selective OX2 receptor agonist with EC50 values are 0.13nM for human OX2.
SB-649868 is a novel, orally active dual orexin receptor antagonist of orexin(OX)1 and OX2 receptor (pKi=9.4 and 9.5 at the OX1 and OX2 receptor, respectively),...
Lemborexant, an orexin OX1/OX2 receptors antagonist, has been found to be effective against insomnia and is just planed a Phase III trail by Eisai.